Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Inclusion Criteria:

1. Unilateral rotator cuff tendinopathy with ≥ 6 weeks to ≤ 6 months symptom durationat baseline.

2. Nocturnal pain in shoulder on at least 3 out of 7 nights in the week prior tobaseline or "positive painful arc test" on examination.

3. Total WORC percentage score ≤ 40 at the screening and baseline visits.

4. Average weekly (i.e., the average of the 7 scores taken once a day) numerical ratingscale (NRS) pain score of ≥5 during the past 7 days prior to the baseline visit.

5. Refractory to standard of care: non-steroidal anti-inflammatory drug (NSAIDs) courseas per local standard practice (if not intolerant or contraindicated) and a courseof physiotherapy over a period of 8 weeks.

6. Participant agreed to remain on stable NSAID dosage regimen (if not intolerant orhaving contraindications; NSAID dose was permitted to be reduced, but not increasedabove dose established at run-in) and physiotherapy regimen from run-in period untilEnd of Study (EOS).

7. Presence of tendinopathy in the affected shoulder on a centrally read MRI (MagneticResonance Imaging), with the following conditions: with no tear or partial tear (maximum 50% tendon thickness; anteroposterior (AP) length maximum 10 mm)

Exclusion Criteria:

1. Rheumatological and non-rheumatological inflammatory diseases, including but notlimited to polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), axialspondyloarthritis (AS: ankylosing spondylitis, nr-axSpA: non-radiographic axialspondyloarthritis), psoriasis (PsO), and rheumatoid arthritis (RA); fibromyalgia orsevere pain disorder unrelated to the target shoulder; gout; and systemic lupuserythematosus.

2. Rheumatoid factor (RF) or anti-cyclic citrullinated peptide (anti-CCP) antibodiespositive at screening.

3. Oral, intramuscular or intravenous (i.v.) corticosteroid treatment within the last 12 weeks prior to randomization, or presence of any condition that might requireintermittent corticosteroid use.

4. Lack of compliance with adhering to NSAID (unless intolerant or contraindicated) andphysiotherapy regimen during run-in period.

5. Positive painful arc test result in contralateral shoulder

6. Inability or unwillingness to undergo MRI of the shoulder (e.g., participants withpacemakers, or metal fragments/foreign objects in the body that were not compatiblewith performing an MRI) to fulfill eligibility criteria (unless centrally read MRIimages acquired within 3 months of baseline could be provided and the quality ofimages was deemed sufficient).